Genzyme, the biotechnology company with significant operations in MetroWest, reported positive results for a Phase-III test of its alemtuzumab drug for treatment of multiple sclerosis.
The test found reduced relapse rates and less worsening of disability in patients using its drug, compared with use of Rebif, another treatment for the disease.
The company is developing alemtuzumab in collaboration with Bayer HealthCare.
Genzyme is a subsidiary of French drug maker Sanofi-Aventis, which acquired it in April.
